Background Clinic-based blood pressure (CBP) has been the default approach for the diagnosis of hypertension, but patients may be misclassified because of masked hypertension (false negative) or 'white coat' hypertension (false positive). The incorporation of other diagnostic modalities, such as home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM), holds promise to improve diagnostic accuracy and subsequent treatment decisions.
Introduction
According to the Centers for Disease Control and Prevention, approximately one out of every three US adults is hypertensive [1] . Uncontrolled hypertension is associated with higher cardiovascular and overall mortality [2] and is present in almost 75% of US adults diagnosed with coronary artery disease, congestive heart failure, cerebrovascular disease, or diabetes mellitus [3] . In 2010, hypertension was estimated to cost the US$76.6 billion in healthcare services, medications, and missed work days [4] .
The US Preventive Services Task Force endorses a Grade A recommendation for screening adults aged 18 years of age and older for hypertension [5] . In a previous review, researchers found several studies that showed the efficacy and effectiveness of detecting elevated blood pressure and introducing antihypertensive treatment as part of routine health visits for reducing future mortality and morbidity; however, evidence on the cost-effectiveness of various blood pressure monitoring techniques was not available [6] .
Traditionally, the diagnosis of hypertension or 'prehypertension' is made by taking blood pressure measurements in the clinic. According to the Joint National Committee VII report [7] , the diagnosis of hypertension in adults is made when the average of two or more diastolic blood pressure (DBP) measurements on at least two visits is at least 90 mmHg or when the average of two or more systolic blood pressure (SBP) measurements on at least two visits is at least 140 mmHg. In addition, 'prehypertension' is defined as having an average DBP of 80-89 mmHg or average SBP of 120-139 mmHg.
However, there are two major caveats to the diagnosis and treatment of hypertension solely on the basis of clinic blood pressure: namely, the possibilities of false-positive and false-negative diagnoses ( Table 1) . 'White coat' hypertension is defined as clinic hypertension (mean SBP is Z 140 mmHg or mean DBP Z 90 mmHg) without ambulatory hypertension (defined as mean awake blood pressure Z 135/85 mmHg) [9] . In the absence of ambulatory blood pressure monitoring (ABPM), these patients are likely to be treated despite having normal 'true' or 'usual' blood pressure, and are thus exposed to unnecessary risks for adverse effects and treatment costs. Conversely, 'masked hypertension' is present when the clinic blood pressure is below 140/90 mmHg but the average blood pressure in one's normal living environment meets the criterion for hypertension [11] -that is, where clinic-based blood pressure (CBP) yields a false-negative diagnosis. These patients are left untreated despite their elevated blood pressure levels. In general, patients with white coat hypertension are shown to have better prognosis than those with true hypertension, and patients with masked hypertension appear to experience worse outcomes than those who are truly normotensive [8] . These observations underlie the limitations of relying on CBP alone for the diagnosis of treatment-eligible patients and the opportunities for out-of-clinic blood pressure measurement modalities to optimize patient outcomes.
Support for the addition of ABPM and/or home blood pressure monitoring (HBPM) measures to the diagnostic algorithms as part of routine care has been modest [5] . However, the UK National Health Services recently revised their blood pressure screening guideline to support the routine use of ABPM to confirm a new diagnosis of hypertension. The new guideline estimated a potential saving of £10 million (US$16 million) over 4-5 years, mainly from the identification of white coat hypertension and subsequent reduction in treatmentassociated costs [12] . Others advocate for the use of HBPM as a cost-effective strategy to augment CBP-based usual care with fewer physician visits [13] [14] [15] [16] [17] , citing its greater accuracy as a measure of 'usual blood pressure', greater reproducibility, greater prognostic value for cardiovascular outcomes, and low cost [17] . Joint National Committee VII guidelines suggested a potential role of blood pressure self-measurement of hypertensive patients [7] , but did not endorse its routine use. International guidelines endorse a wider use of HBPM for monitoring treatment [18] [19] [20] . The limited uptake and reimbursement for ABPM and HBPM may be because of a knowledge gap of its cost-effectiveness compared with CBP. In this article, we provide an overview of the existing literature on the comparative cost and cost-effectiveness of ABPM and HBP for hypertension screening.
Materials and methods
Independent searches of PubMed, Medline, and the Tufts Cost Effectiveness Analysis (CEA) Registry were carried out by authors A.M.K. and M.N. for studies published in the past 25 years. Citations and reference lists were also reviewed to identify additional studies. We used the following search terms: adult, hypertension, blood pressure, screening, diagnosis; cost-effectiveness, cost-benefit, cost analysis, cost utility, cost impact, clinic, ambulatory, home; multiple combinations of search terms were used to maximize results from the searches. We included original English language studies that compared two or more modalities of blood pressure measurement for the purposes of primary prevention. Letters and editorials were excluded. We also excluded studies that were restricted to subpopulations of pregnant and/or preeclamptic patients; patients with specific comorbidities (i.e. diabetes, coronary artery disease); and/or patients undergoing treatment using a particular drug or device. All eligible articles were audited by A.M.K. and J.D.N. independently, and disagreements were resolved by all authors.
We report the year of publication, country, study population, study design, time horizon, and the main findings. We also report the original cost figures as well as standardized 2011 US dollars to allow comparisons across studies including various currencies and years of analysis.
Results
Fourteen studies were identified to fulfill our eligibility criteria ( Table 2 ). Nine of the 14 studies are clinical trials, whereas five are model-based decision analyses. The earliest study was published in 1988 [21] . Seven out of 14 studies were carried out in Europe; four were carried out in the USA; two were carried out in Japan; and one was carried out in Australia. Nine studies compared ABPM with CBP alone [21] [22] [23] [24] [25] [26] [27] [28] [29] , four studies compared HBPM with CBP [13] [14] [15] [16] , and one study compared all three [12] .
Comparing ambulatory blood pressure monitoring to clinic-based blood pressure
In general, compared with CBP alone, most researchers found ABPM to be cost saving. This cost saving was achieved mainly through increases in diagnostic accuracy, resulting in a reduction in overtreatment because of false-positive diagnoses of hypertension on the basis of CBP alone [12, [22] [23] [24] [27] [28] [29] . For example, in two separate studies, Krakoff et al. [21, 29] found that over a period of 3 years, the cumulative costs of treatment for mild hypertension are lower for those using ABPM compared with CBP only. These researchers also estimated a 3-14% reduction in medical costs (which correlated with a Typically defined as the average blood pressure during awake hours. ABPM is usually viewed as the gold standard to reflect the average out-of-clinic blood pressure status. b Masked hypertension carries a higher risk for future cardiovascular events from untreated hypertension [8] . c White coat hypertension results in unnecessary treatment costs and risk for adverse effects. They constitute B20% of newly diagnosed hypertensive patients [9] , with a 10% per year progression rate to sustained hypertension [10] . 10-23% reduction in treated patient-days) as long as annual treatment costs are no more than US$300. Yarows et al. [30] estimated that the cessation of unnecessary antihypertensives in patients with white coat hypertension could offset the cost of ABPM after 1 year when ABPM costs US$188 or less. When ABPM was used as a secondary diagnostic modality, Pierdomenico et al. [23] found a saving of US$110 819 by using ABPM every 2 years over a 6-year period, compared with annual screening using CBP alone. Rodriguez-Roca et al. [27] found that the cost of achieving a well-controlled hypertension case is h940 (US$1169) with CBP and h238 (US$296) with ABPM, resulting in h115 (US$143 in 2011) per additional well-controlled case achieved. In a secondary prevention study by Lorgelly et al. [26] , ABPM successfully identified patients with white coat hypertension, but at an annual cost of £3612 (US$6641 in 2011).
Long-term savings were also found by a number of additional ABPM studies [24, 28] . After measuring both consultation and medication costs, Aitken and Addison [24] reported that the initial costs of ABPM were recouped after 1-2 years. Similarly, Ewald and Pekarsky [28] constructed a model to evaluate the cost and effectiveness of ABPM conducted every 1, 2, or 3 years. Over a 7-year period, all three strategies broke even after the third year, with subsequent savings ranging from US$34 to US$53 per year per patient.
However, two research teams found no net savings of ABPM compared with CBP. In a randomized-controlled trial published in 1997 by Staessen et al. [25] , the researchers found that, despite more patients in the ABPM arm being considered a false positive and having their antihypertensive treatment discontinued than in the CBP arm, and more patients in the CBP arm progressing to multidrug treatment than in the ABPM arm, the savings at 1 year were not sufficient to offset the cost of ABPM. However, the range of follow-up for this study was only 85-258 days, which might be an inadequate time period to observe savings. Similarly, Lorgelly et al. [26] found that ABPM increased the cost of hypertension control at a rate of £31 (US$57 in 2011) per patient over 1 year.
Comparing home blood pressure monitoring to clinic-based blood pressure There were two randomized-controlled trials comparing HBPM with CBP. Staessen et al. [16] found that HBPM was associated with worse hypertension management despite marginally lower costs. At 1 month, the average medical costs per 100 patients were US$4473 with HBPM versus US$4921 without HBPM; however, the mean blood pressure was also higher in the HBPM group. General well-being and left ventricular mass did not appear to differ between the two groups. Note, however, that the authors used a threshold for HBPM of 140/ 90 mmHg to define hypertension control, rather than the generally accepted 135/85 mmHg cutoff. In contrast, in their year-long clinical trial, Soghikian et al. [15] found that the mean costs for hypertension care were 29% less in patients managed through HBPM compared with usual clinic-based care.
Three of the four modeled analyses comparing HBPM with CBP found HBPM to be cost-effective [13] [14] [15] [16] .
Using data from the Ohasama study and a Markov model, Fukunaga et al. [13] estimated that incorporating HBPM into the diagnosis of hypertension in the Japanese population could reduce medical costs by US$1.56 million for every 1000 patients over 5 years. When they varied the assumed prevalence of white coat hypertension from 8.2 to 24.7% in the sensitivity analysis, the resulting cost reduction ranged from US$0.8 to 2.0 million. Using the same data but using a decision tree model, Funahashi et al. [14] estimated that broad implementation of HBPM could result in a saving of US$9.3 billion in hypertensionrelated medical costs in Japan. These cost savings came mainly from identifying white coat hypertension. Moreover, HBPM also contributes toward better control and prognosis of true hypertensives, saving BUS$28 million in annual medical costs from the prevention of hypertension-related complications and US$39 million annually from stroke prevention. It is worth noting that, because stroke occurs at a greater incidence in the Japanese population relative to coronary heart disease (whereas coronary artery disease and myocardial infarctions are much more prevalent than stroke in the USA and Western European societies), their study placed a greater emphasis on the role of hypertension control in stroke prevention.
Comparing ambulatory blood pressure monitoring, home blood pressure monitoring, and clinic-based blood pressure
Using a state-transition Markov model, Lovibond et al. [12] is the only study that compared ABPM, HBPM, and CBP. The study was based on the sensitivity and specificity of CBP [sensitivity 85.6% (95% confidence interval (CI) 81.0-89.2); specificity 45.9% (95% CI 33.0-59.
3)], HBPM [sensitivity 85.7% (95% CI 78.0-91.2); specificity 62.4% (95% CI 48.0-75.0)], and ABPM (both 100%, considered gold standard) on a published metaanalysis [31] . From the perspective of the British National Health Services, the study found that ABPM was cost saving in reducing unnecessary treatment and future risks of coronary heart disease and stroke for men and women of all ages.
Discussion
On the basis of our review, existing studies suggest that supplementing CBP with HBPM or ABPM is costeffective for improving the diagnosis of hypertension and subsequent treatment decisions. Although differences in the study population and analytic methods exist, this conclusion is consistent across the literature reviewed. These economic evaluations suggested that adding HBPM or ABPM after detecting elevated blood pressure in the clinic setting could be worthwhile for identifying white coat hypertension and avoiding unnecessary treatment.
Despite these consistent findings on the comparative values of HBPM and ABPM, the translation of these findings into practice is modest and broad implementation of these modalities into clinical practice has not occurred. This may be because of the marginal cost savings found in some studies.
As the clinical benefit of blood pressure measures hinges on the probabilities of false positive and false negatives ( Table 1) , identification of subpopulations most likely to be misclassified by CBP alone will be important in maximizing cost-effectiveness. As noted by Krakoff [29] , the use of ABPM to diagnose hypertension may be most cost-effective when the prevalence of white coat hypertension is high and when the annual incidence of new hypertension is low. In four population-based European studies, researchers found that ambulatory pressure shows much less increase with age than CBP [32] [33] [34] [35] . We found few studies examining the compliance issues associated with HBPM/ABPM. As the utility of these modalities depends on patient cooperation, existing studies on the basis of trial populations or modeling assumptions are likely to represent an overestimate of the cost-effectiveness of these modalities.
Both ABPM and HBPM can add accuracy and value beyond simply correcting the CBP measurement. For instance, ABPM can indicate nocturnal hypertension, a relatively new marker of cardiac risk that has been shown to further refine cardiovascular risk stratification beyond conventional blood pressure measurement, both in untreated individuals with white coat hypertension and in those with resistant hypertension [36, 37] . ABPM is also currently considered as the 'gold standard' for the prediction of risk; however, the role of ABPM in the diagnosis of masked hypertension is uncertain, and it remains the most expensive of the three modalities [38] . The degree to which HBPM, a less expensive out-ofoffice option, can adequately substitute for ABPM is unknown. However, there is increasing evidence that HBPM is a good predictor of left ventricular hypertrophy and cardiovascular events, including mortality. HBPM also has better prognostic accuracy than CBP for predicting the future development of hypertension, and may be particularly useful for monitoring the effects of antihypertensive treatment [30, 39, 40] . HBPM has the added bonus of eliminating the white coat effect entirely, and can considerably increase patients' awareness of their own blood pressure, which may lead to better compliance with treatment [41] . However, HBPM may not be suitable for all patients (e.g. obese patients with large arm sizes or the elderly) and is subject to the same operator issues as CBP. Although most studies show that HBPM lowers costs, one study (but not others) also found that when used alone, it decreased blood pressure control [16] .
On the basis of our review, existing studies have characterized the clinical benefits of HBPM and ABPM for the identification of white coat hypertension (false positives); however, more research is required to assess how HBPM and ABPM may best be used to identify masked hypertension (false negatives). A reasonable approach may be to prescribe ABPM or HBPM for patients with CBP in the high-normal range (130-139/85-89 mmHg) or the prehypertensive (120-139/80-89 mmHg) range. One might also consider the presence/absence of other cardiovascular risk factors in deciding who could benefit most from ABPM or HBPM following a normal CBP. The value of identifying individuals with masked hypertension parallels the wellestablished clinical benefit and cost-effectiveness of treating previously undiagnosed hypertension. However, unlike observing cost savings from avoiding treatment among white coat hypertensives, the cost savings will come from downstream events avoided and therefore the research will require a longer follow-up time. This need for a long-term perspective highlights the value of modelbased studies that enable us to weigh immediate set-up costs with downstream treatment costs avoided, possibly several decades later [12] [13] [14] 29] .
It is worth noting that researchers and clinicians should not overlook ways to improve the accuracy of CBP. CBP uses the traditional auscultatory technique with a trained technician and a sphygmomanometer. Various types of equipment are still used, including mercury (rarely); aneroid devices (require frequent calibration); and automatic devices with electronic transducers, which are becoming increasingly more common [42] and can potentially minimize the white coat effect of CBP at a reasonable cost [43] . Training of the operator, positioning of the patient, and cuff size can all make a difference in measurement, and are all factors that contribute toward the poor correlation between CBP and other types of blood pressure measurement, especially outside the research setting. In addition, there needs to be greater recognition of the fact that blood pressure is a dynamic variable, of which CBP provides only a snapshot. Even if CBP is the sole diagnostic assessment method, treatment decisions should be based on multiple visits, with multiple readings taken during each visit.
As the UK National Health Services begins to cover ABPM following an initial CBP assessment as part of routine care [12] , we anticipate increased discussion about the potential utility of following similar diagnostic algorithms in US clinical guidelines. Additional populationbased evidence from the UK will also fill key knowledge gaps on the longer-term merits and unintended consequences of these practices. Furthermore, as the field of cardiovascular prevention moves toward a global risk-based approach rather than a single-risk factor approach, the diagnostic accuracy of blood pressure may have implications beyond hypertension treatment. For instance, the Adult Treatment Panel 3 cholesterol treatment guideline determines candidacy and treatment goal for lipid-lowering therapy on the basis of predicted 10-year Framingham risk for coronary heart disease. If one has two or more noncholesterol risk factors such as elevated blood pressure, even borderline LDL levels may be sufficient to be classified as statin-eligible. Considering the day-to-day variability and diagnostic inaccuracies of blood pressure measures, it is possible that a false-positive CBP reading results in both unnecessary antihypertensive and cholesterol-lowering medications. Future research should evaluate the full spectrum of clinical and cost implications of implementing secondary modalities in clinical practice, for both primary and secondary prevention, and for a sufficiently long time frame. The identification of optimal thresholds for secondary measurement modality and for treatment initiation, possibly for different demographic subgroups, will have a huge impact on driving the costefficiency of hypertension screening at the population level.
